Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-20
    E.g., 2018-02-20

Archive Search


254495 items
4:15 PM, Feb 20, 2018  |  BC Extra | Company News

Takeda, Wave in CNS nucleic acid deal

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and Wave Life Sciences Ltd. (NASDAQ:WVE) partnered to develop and commercialize nucleic acid therapies to treat CNS diseases. Wave will receive an upfront payment of $170 million, including $110 million in...
4:06 PM, Feb 20, 2018  |  BC Extra | Clinical News

Eli Lilly stops Phase II trial of BTK inhibitor in RA

Eli Lilly and Co. (NYSE:LLY) discontinued the Phase II RAjuvenate trial of HM71224 (LY3337641) to treat rheumatoid arthritis after a planned analysis showed that the difference between the active and placebo control arms "was not...
3:57 PM, Feb 20, 2018  |  BC Extra | Company News

JNJ execs launch Centyrins newco Aro

Two former Johnson & Johnson (NYSE:JNJ) executives have co-founded Aro Biotherapeutics Co. (Philadelphia, Pa.) to develop Centyrins for extra-hepatic, receptor-mediated delivery of oligonucleotides and other payloads. Aro President and CEO Susan Dillon was previously global...
3:53 PM, Feb 20, 2018  |  BC Extra | Company News

Management tracks: Cell Medica, Iterum

Cancer immunotherapy company Cell Medica Ltd. (London, U.K.) appointed Kevin Boyle as CFO. He was CFO at FloWorks International LLC (Houston, Texas). Anti-infectives company Iterum Therapeutics Ltd. (Dublin, Ireland) hired Jeff Schaffnit as chief commercial officer....
3:46 PM, Feb 20, 2018  |  BC Extra | Company News

Everest gets rights to Tetraphase antibiotic

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) granted C-Bridge-backed Everest Medicines Ltd. (Boston, Mass.) exclusive rights to develop and commercialize eravacycline (TP-434) in China, Taiwan, Hong Kong, Macau, South Korea and Singapore. Tetraphase will receive $7 million up front...
3:06 PM, Feb 20, 2018  |  BC Extra | Clinical News

Aimmune's peanut allergy therapy meets in Phase III

Aimmune Therapeutics Inc. (NASDAQ:AIMT) said AR101 met the primary endpoint in the Phase III PALISADE trial to treat peanut allergy, but also reported that a greater proportion of patients in the active arm discontinued treatment...
2:35 PM, Feb 20, 2018  |  BC Extra | Company News

Voyager, AbbVie partner for AD gene therapies

Gene therapy company Voyager Therapeutics Inc. (NASDAQ:VYGR) jumped $4.30 (22%) to $23.66 on Tuesday after partnering with AbbVie Inc. (NYSE:ABBV) to develop gene therapies to express microtubule-associated protein tau (tau; MAPT; FTDP-17) antibodies to treat...
2:09 PM, Feb 20, 2018  |  BC Extra | Company News

MiMedx falls on delayed earnings filing due to internal audit

Regenerative medicines company MiMedx Group Inc. (NASDAQ:MDXG) fell $5.72 (40%) to $8.75 on Tuesday after announcing it will delay the release of its fourth quarter and fiscal-year 2017 financial results as the company conducts an...
1:48 PM, Feb 20, 2018  |  BC Extra | Company News

Ionis, AstraZeneca in antisense kidney disease deal

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) granted AstraZeneca plc (LSE:AZN; NYSE:AZN) worldwide rights to develop and commercialize antisense candidate IONIS-AZ5-2.5Rx (AZD2373), which is in development to treat an undisclosed genetically associated form of kidney disease. Ionis will...
1:10 PM, Feb 20, 2018  |  BC Extra | Preclinical News

New compound kills tumor cells with spliceosome mutations

In a Nature Medicine study, researchers at H3 Biomedicine Inc. (Cambridge, Mass.) described development and preclinical proof-of-efficacy data for Phase I candidate H3B-8800, a potentially first-in-class mRNA splicing inhibitor for cancers harboring spliceosome mutations. Mutations...